KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Other Non-Current Liabilities (2016 - 2022)

Inovio Pharmaceuticals' Other Non-Current Liabilities history spans 13 years, with the latest figure at $710348.0 for Q3 2022.

  • For Q3 2022, Other Non-Current Liabilities rose 1007.48% year-over-year to $710348.0; the TTM value through Sep 2022 reached $710348.0, up 1007.48%, while the annual FY2021 figure was $14826.0, 74.29% down from the prior year.
  • Other Non-Current Liabilities for Q3 2022 was $710348.0 at Inovio Pharmaceuticals, up from $14826.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $4.5 million in Q3 2019 and bottomed at $14826.0 in Q4 2021.
  • The 5-year median for Other Non-Current Liabilities is $64141.0 (2021), against an average of $463420.4.
  • The largest annual shift saw Other Non-Current Liabilities skyrocketed 4418.88% in 2019 before it plummeted 99.12% in 2020.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $99669.0 in 2018, then crashed by 62.93% to $36943.0 in 2019, then soared by 56.09% to $57663.0 in 2020, then plummeted by 74.29% to $14826.0 in 2021, then soared by 4691.23% to $710348.0 in 2022.
  • Per Business Quant, the three most recent readings for INO's Other Non-Current Liabilities are $710348.0 (Q3 2022), $14826.0 (Q4 2021), and $64141.0 (Q3 2021).